《眼科学报》中文版（月刊,ISSN:1000-4432;CN:44-1119/R）创刊于1985年，是由中华人民共和国教育部主管、中山大学主办、中山大学中山眼科中心出版及发行的国际化医学学术期刊。由中山大学中山眼科中心林浩添教授担任主编，中山大学中山眼科中心刘臻臻教授担任执行主编，由来自20多个国家的国际知名眼科专家组成编委会。
《眼科学报》中文版收录于Chemical Abstract(CA)、ICI Journals Master List(哥白尼精选期刊数据)、中国期刊全文数据库(知网)、中国核心期刊(遴选)数据库(万方)、中文科技期刊数据库(维普)等国内外重要数据库，是国家重点研发计划“专业内容知识聚合服务平台”创新服务示范单位。
中山大学中山眼科中心简介
中山大学中山眼科中心是国家卫生健康委属委管唯一的眼科专科医院，是唯一的眼病防治全国重点实验室依托单位。中山眼科中心是眼科学国家创新高地。在眼科再生医学、生物信息、医学人工智能等做出了具有世界影响的贡献：利用内源性干细胞原位再生组织晶状体，2016年发表在Nature，并被Nature Medicine评为同年“全球医学八大进展之一”，这是我国医学界首次获评；青少年近视眼研究结果引起了习近平总书记的重视并为此重要批示；发现增加户外活动可有效预防青少年近视眼，发表在JAMA杂志，成为世卫组织和国家八部委近视眼防控方案；创新眼科人工智能的临床应用；原研白内障的I类新药以13.8亿元实现转化。获11项国家科技进步奖（第一完成单位）。
中山眼科中心是我国最具国际影响力的眼科机构。是世界卫生组织（WHO）在中国唯一眼科合作机构，亚太眼科学会总部所在地（第一个在中国大陆的国际医学学术组织），是中、英、美国家眼科研究联盟单位。
稿件处理周期
初审: 3天
同行评议: 2周
在线出版: 稿件被接受后1周内
正式出版: 稿件被接受后1~3个月内。论著文章将优先出版
Founded in 1985, Yanke Xuebao (parallel title: Eye Science) (monthly, ISSN: 1000-4432; CN: 44-1119/R) is an international academic medical journal, governed by the Ministry of Education of the People's Republic of China, sponsored by Sun Yat-sen University, and published and distributed by the Zhongshan Ophthalmic Center, Sun Yat-sen University. Professor Haotian Lin (Zhongshan Ophthalmic Center, Sun Yat-sen University) holds the position of Editor-in-Chief, and Professor Zhenzhen Liu (Zhongshan Ophthalmic Center, Sun Yat-sen University) serves as Executive Editor-in-Chief. The editorial board consists of multiple distinguished ophthalmology experts from over 20 countries.
The journal has been included in multiple databases both in China and abroad, such as American Chemical Abstracts (CA), ICI Journals Master List, China National Knowledge Infrastructure (CNKI), Chinese Core Journals (Selection) Database (Wanfang), and Chinese Science and Technology Periodical Database (Chongqing VIP). It stands as an exemplar of innovative service for the "Professional Content & Knowledge Aggregation Service Platform", which is a national key research and development initiative.
Overview of Zhongshan Ophthalmic Center
Zhongshan Ophthalmic Center of Sun Yat-sen University is the only specialized ophthalmic hospital directly managed by the National Health Commission of China. It serves as the affiliated institution of the only National Key Laboratory for Ophthalmological Disease Prevention and Control. The Center is a national leader in ophthalmological innovation, making globally recognized contributions in areas such as regenerative ophthalmic medicine, bioinformatics, and medical artificial intelligence. Notably, the Center pioneered the in-situ regeneration of the lens using endogenous stem cells, a breakthrough published in Nature in 2016 and recognized by Nature Medicine as one of the "Top Eight Global Medical Advances" of the year, the first such honor for China's medical community. The research on myopia in adolescents received significant attention from President Jinping Xi, who issued an important directive in response. The Center's discovery that increased outdoor activities can effectively prevent myopia in adolescents was published in JAMA and has been incorporated into myopia prevention programs by both the World Health Organization (WHO) and Chinese government ministries. In addition, the Center has innovated in clinical applications of ophthalmic AI and successfully developed a new cataract drug, achieving a record-breaking technology transfer deal worth CNY 1.38 billion. The Center has won 11 National Science and Technology Progress Awards as the leading institution.
Zhongshan Ophthalmic Center is the most internationally influential ophthalmic institution in China. It is the only WHO collaborating center for ophthalmology in China and hosts the Asia-Pacific Academy of Ophthalmology, marking the first international medical academic organization based in Mainland China. The Center is also a member of ophthalmic research alliances in China, the UK, and the US.
Submission Turnaround Time:
Initial Review: 3 days
Peer Review: 2 weeks
Online Publication: Within 1-week post-acceptance
Formal Publication: Between 1 to 3 months post-acceptance, with original research articles receiving publication priority
